4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

or therapeutic medical strategies. However, the ESC Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to make appropriate and …

Risk stratification scheme. Risk stratification aiming at assessing the risk of VAs and SCD in
patients with MVP, involving two phases based on the clinical and imaging context and the …

Background Mitral valve prolapse (MVP) is often considered benign but recent suggestion of
an arrhythmic MVP (AMVP) form remains incompletely defined and uncertain. Objectives …

Background: Mitral annulus disjunction (MAD) is an abnormal atrial displacement of the
mitral valve leaflet hinge point. MAD has been associated with mitral valve prolapse (MVP) …

Despite a 2% to 3% prevalence of echocardiographically defined mitral valve prolapse
(MVP) in the general population, the actual burden, risk stratification, and treatment of the so …

Background: Mitral valve prolapse (MVP) is a frequent disease that can be complicated by
mitral regurgitation (MR), heart failure, arterial embolism, rhythm disorders, and death. Left …

Background Recent studies reported left ventricular (LV) fibrosis in patients with primary
mitral regurgitation (MR) thought to be principally due to mitral valve prolapse (MVP) …

Objectives The aim of this study was to assess in patients with mitral valve prolapse (MVP)
mitral annular disjunction (MAD) prevalence, phenotypic characteristics, and long-term …

Mitral regurgitation (MR) is a common valvular heart disease and is the second most
frequent indication for heart valve surgery in Western countries. Echocardiography is the …